Do analysts rate PTPI or CNSP?

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 262.32%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PTPI or CNSP more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% CNS Pharmaceuticals N/A -204.25% -141.87%

Is PTPI or AMPE more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Ampio Pharmaceuticals N/A N/A N/A

Do analysts prefer PTPI or CARM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PTPI or VINC more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Vincerx Pharma N/A -248.33% -132.73%

Is PTPI or CLVR more profitable?

Clever Leaves' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Clever Leaves N/A N/A N/A

Petros Pharmaceuticals (PTPI) Competitors

$0.0027 0.00 (-20.59%)

As of 08/14/2026 03:57 PM Eastern

Compare

PTPI vs. CNSP, AMPE, CARM, VINC, and CLVR

Should you buy Petros Pharmaceuticals stock or one of its competitors? Petros Pharmaceuticals's main competitors and comparable companies include CNS Pharmaceuticals (CNSP), Ampio Pharmaceuticals (AMPE), Carisma Therapeutics (CARM), Vincerx Pharma (VINC), and Clever Leaves (CLVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 262.32%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Petros Pharmaceuticals has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 beat CNS Pharmaceuticals' score of -0.07 indicating that Petros Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
CNS Pharmaceuticals	Neutral

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 8.2% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$1.64	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Ampio Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Ampio Pharmaceuticals	Neutral

Petros Pharmaceuticals has higher revenue and earnings than Ampio Pharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$1.64	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Ampio Pharmaceuticals' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Ampio Pharmaceuticals	N/A	N/A	N/A

Petros Pharmaceuticals has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market.

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 8.2% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Petros Pharmaceuticals beats Ampio Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Carisma Therapeutics?

Petros Pharmaceuticals (NASDAQ:PTPI) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Carisma Therapeutics	Neutral

Petros Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Petros Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$1.64	N/A
Carisma Therapeutics	$10.77M	0.01	-$60.48M	$0.73	0.00

Petros Pharmaceuticals has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.09, indicating that its share price is 1,009% less volatile than the broader market.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 8.2% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Petros Pharmaceuticals and Carisma Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Vincerx Pharma?

Petros Pharmaceuticals (NASDAQ:PTPI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 8.2% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Petros Pharmaceuticals has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$1.64	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Vincerx Pharma	N/A	-248.33%	-132.73%

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 7 of the 9 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Clever Leaves?

Petros Pharmaceuticals (NASDAQ:PTPI) and Clever Leaves (NASDAQ:CLVR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Clever Leaves	Neutral

Petros Pharmaceuticals has higher earnings, but lower revenue than Clever Leaves. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$1.64	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

Clever Leaves' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Clever Leaves	N/A	N/A	N/A

Petros Pharmaceuticals has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, suggesting that its share price is 381,513% more volatile than the broader market.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Clever Leaves beats Petros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTPI vs. The Competition

Export

Metric	Petros Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84K	$11.86B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	0.00	775.15	269.06	25.28
Price / Sales	0.02	743.25	601.61	91.31
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.00	11.60	12.91	6.24
Net Income	-$8.16M	$2.76B	$3.45B	$347.60M
7 Day Performance	N/A	0.09%	1.10%	1.06%
1 Month Performance	N/A	0.00%	1.32%	0.81%
1 Year Performance	N/A	145.10%	62.43%	20.90%

Petros Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTPI Petros Pharmaceuticals	N/A	$0.00 -20.6%	N/A	-91.3%	$84K	$5.11M	N/A	20	Gap Down
CNSP CNS Pharmaceuticals	3.5702 of 5 stars	$5.40 +0.7%	$20.00 +270.4%	-8.5%	$7.83M	N/A	N/A	5	Earnings Report Upcoming Earnings
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
CARM Carisma Therapeutics	0.2587 of 5 stars	$0.00 flat	$1.00 +39,900.0%	-99.2%	$105K	$10.77M	0.00	20
VINC Vincerx Pharma	N/A	$0.01 flat	N/A	-67.6%	$66K	N/A	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTPI) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, AMPE, CARM, VINC, and CLVR

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Ampio Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Carisma Therapeutics?

Summary

How does Petros Pharmaceuticals compare to Vincerx Pharma?

Summary

How does Petros Pharmaceuticals compare to Clever Leaves?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, AMPE, CARM, VINC, and CLVR

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Do analysts rate PTPI or CNSP?

Which has more risk and volatility, PTPI or CNSP?

Does the media favor PTPI or CNSP?

Do insiders and institutionals have more ownership in PTPI or CNSP?

Which has higher valuation and earnings, PTPI or CNSP?

Is PTPI or CNSP more profitable?

Summary

How does Petros Pharmaceuticals compare to Ampio Pharmaceuticals?

Does the media favor PTPI or AMPE?

Which has preferable earnings and valuation, PTPI or AMPE?

Is PTPI or AMPE more profitable?

Which has more risk and volatility, PTPI or AMPE?

Do insiders and institutionals hold more shares of PTPI or AMPE?

Summary

How does Petros Pharmaceuticals compare to Carisma Therapeutics?

Does the media favor PTPI or CARM?

Is PTPI or CARM more profitable?

Do analysts prefer PTPI or CARM?

Which has stronger valuation and earnings, PTPI or CARM?

Which has more volatility and risk, PTPI or CARM?

Do institutionals and insiders have more ownership in PTPI or CARM?

Summary

How does Petros Pharmaceuticals compare to Vincerx Pharma?

Do insiders & institutionals believe in PTPI or VINC?

Which has more risk & volatility, PTPI or VINC?

Does the media favor PTPI or VINC?

Which has stronger valuation and earnings, PTPI or VINC?

Is PTPI or VINC more profitable?

Summary

How does Petros Pharmaceuticals compare to Clever Leaves?

Does the media prefer PTPI or CLVR?

Which has preferable earnings and valuation, PTPI or CLVR?

Is PTPI or CLVR more profitable?

Which has more risk & volatility, PTPI or CLVR?

Do insiders and institutionals believe in PTPI or CLVR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools